Virginie Marcel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6968649/publications.pdf

Version: 2024-02-01

48 papers	2,739 citations	201575 27 h-index	189801 50 g-index
54 all docs	54 docs citations	54 times ranked	4203 citing authors

#	Article	IF	Citations
1	p53 Acts as a Safeguard of Translational Control by Regulating Fibrillarin and rRNA Methylation in Cancer. Cancer Cell, 2013, 24, 318-330.	7.7	246
2	Evidence for rRNA 2â€²-O-methylation plasticity: Control of intrinsic translational capabilities of human ribosomes. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 12934-12939.	3.3	197
3	G-quadruplex structures in TP53 intron 3: role in alternative splicing and in production of p53 mRNA isoforms. Carcinogenesis, 2011, 32, 271-278.	1.3	186
4	Biological functions of p53 isoforms through evolution: lessons from animal and cellular models. Cell Death and Differentiation, 2011, 18, 1815-1824.	5.0	173
5	Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Therapy, 2011, 18, 2-11.	2.2	151
6	Recent advances in p53 research: an interdisciplinary perspective. Cancer Gene Therapy, 2009, 16, 1-12.	2.2	140
7	Î”160p53 is a novel Nâ€terminal p53 isoform encoded by Î”133p53 transcript. FEBS Letters, 2010, 584, 4463-4468.	3.3	110
8	Ribosome biogenesis: An emerging druggable pathway for cancer therapeutics. Biochemical Pharmacology, 2019, 159, 74-81.	2.0	109
9	Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Letters, 2008, 261, 21-25.	3.2	94
10	2â€²-O-Methylation of Ribosomal RNA: Towards an Epitranscriptomic Control of Translation?. Biomolecules, 2018, 8, 106.	1.8	88
11	Ribosomal Proteins Regulate MHC Class I Peptide Generation for Immunosurveillance. Molecular Cell, 2019, 73, 1162-1173.e5.	4.5	81
12	Modulation of p53Î² and p53Î³ expression by regulating the alternative splicing of TP53 gene modifies cellular response. Cell Death and Differentiation, 2014, 21, 1377-1387.	5.0	80
13	Host microRNA molecular signatures associated with human H1N1 and H3N2 influenza A viruses reveal an unanticipated antiviral activity for miR-146a. Journal of General Virology, 2013, 94, 985-995.	1.3	76
14	p53, a translational regulator: contribution to its tumour-suppressor activity. Oncogene, 2015, 34, 5513-5523.	2.6	71
15	p53 isoforms - A conspiracy to kidnap p53 tumor suppressor activity?. Cellular and Molecular Life Sciences, 2009, 66, 391-406.	2.4	68
16	TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis. Journal of Medical Genetics, 2009, 46, 766-772.	1.5	64
17	p53 regulates the transcription of its Î”133p53 isoform through specific response elements contained within the TP53 P2 internal promoter. Oncogene, 2010, 29, 2691-2700.	2.6	60
18	Emerging Role of Eukaryote Ribosomes in Translational Control. International Journal of Molecular Sciences, 2019, 20, 1226.	1.8	49

#	Article	IF	Citations
19	Diverse p63 and p73 isoforms regulate Î”133p53 expression through modulation of the internal TP53 promoter activity. Cell Death and Differentiation, 2012, 19, 816-826.	5.0	48
20	A meta-analysis of cancer risk associated with the TP53 intron 3 duplication polymorphism (rs17878362): geographic and tumor-specific effects. Cell Death and Disease, 2013, 4, e492-e492.	2.7	43
21	40 Years of Research Put p53 in Translation. Cancers, 2018, 10, 152.	1.7	43
22	snoRNAs Offer Novel Insight and Promising Perspectives for Lung Cancer Understanding and Management. Cells, 2020, 9, 541.	1.8	41
23	Ribosomal RNA 2â€²O-methylation as a novel layer of inter-tumour heterogeneity in breast cancer. NAR Cancer, 2020, 2, zcaa036.	1.6	40
24	Cellular transcriptional profiling in human lung epithelial cells infected by different subtypes of influenza A viruses reveals an overall down-regulation of the host p53 pathway. Virology Journal, 2011, 8, 285.	1.4	38
25	Influenza A Viruses Control Expression of Proviral Human p53 Isoforms p53Î² and Î”133p53Î±. Journal of Virology, 2012, 86, 8452-8460.	1.5	36
26	Ribosome heterogeneity in tumorigenesis: the rRNA point of view. Molecular and Cellular Oncology, 2015, 2, e983755.	0.3	34
27	Iron and hepcidin mediate human colorectal cancer cell growth. Chemico-Biological Interactions, 2020, 319, 109021.	1.7	33
28	Age at cancer onset in germline TP53 mutation carriers: association with polymorphisms in predicted G-quadruplex structures. Carcinogenesis, 2014, 35, 807-815.	1.3	29
29	Ribosome Biogenesis Alterations in Colorectal Cancer. Cells, 2020, 9, 2361.	1.8	28
30	Impact of G-quadruplex structures and intronic polymorphisms rs17878362 and rs1642785 on basal and ionizing radiation-induced expression of alternative p53 transcripts. Carcinogenesis, 2014, 35, 2706-2715.	1.3	25
31	Expression Profiling of Ribosome Biogenesis Factors Reveals Nucleolin as a Novel Potential Marker to Predict Outcome in AML Patients. PLoS ONE, 2017, 12, e0170160.	1.1	25
32	Translational reprogramming of colorectal cancer cells induced by 5-fluorouracil through a miRNA-dependent mechanism. Oncotarget, 2017, 8, 46219-46233.	0.8	25
33	Alteration of ribosome function upon 5-fluorouracil treatment favors cancer cell drug-tolerance. Nature Communications, 2022, 13, 173.	5.8	23
34	A novel view on an old drug, 5-fluorouracil: an unexpected RNA modifier with intriguing impact on cancer cell fate. NAR Cancer, 2021, 3, zcab032.	1.6	22
35	The Nonstructural NS1 Protein of Influenza Viruses Modulates TP53 Splicing through Host Factor CPSF4. Journal of Virology, 2019, 93, .	1.5	21
36	Detecting p53 Isoforms at Protein Level. Methods in Molecular Biology, 2013, 962, 15-29.	0.4	17

#	Article	IF	Citations
37	The associations of sequence variants in DNA-repair and cell-cycle genes with cancer risk: genotypeâ€“phenotype correlations. Biochemical Society Transactions, 2009, 37, 527-533.	1.6	14
38	Detecting and Quantifying p53 Isoforms at mRNA Level in Cell Lines and Tissues. Methods in Molecular Biology, 2013, 962, 1-14.	0.4	14
39	2â€²O-Ribose Methylation of Ribosomal RNAs: Natural Diversity in Living Organisms, Biological Processes, and Diseases. Cells, 2021, 10, 1948.	1.8	13
40	Druggable Nucleolin Identifies Breast Tumours Associated with Poor Prognosis That Exhibit Different Biological Processes. Cancers, 2018, 10, 390.	1.7	12
41	Analysis of the rRNA methylation complex components in pediatric B-cell precursor acute lymphoblastic leukemia: A pilot study. Advances in Clinical and Experimental Medicine, 2020, 29, 107-113.	0.6	12
42	Ribosomes: the future of targeted therapies?. Oncotarget, 2013, 4, 1554-1555.	0.8	11
43	Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer. BMC Cancer, 2022, 22, 526.	1.1	10
44	Heterogeneity and dynamic of EMT through the plasticity of ribosome and mRNA translation. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188718.	3.3	8
45	Victoria: A multicentric, randomized, open-label, phase I/II of mTOR inhibitor (VISTUSERTIB) combined with anastrozole in patients with hormone receptor-positive advanced/metastatic endometrial cancerâ€”A CLIPP program INCA in collaboration with GINECO group.. Journal of Clinical Oncology, 2021, 39, 5507-5507.	0.8	5
46	Ribosomal RNA Methylation and Cancer. , 2015, , 115-139.		4
47	Uncovering the Translational Regulatory Activity of the Tumor Suppressor BRCA1. Cells, 2020, 9, 941.	1.8	3
48	Externalized Keratin 8: A Target at the Interface of Microenvironment and Intracellular Signaling in Colorectal Cancer Cells. Cancers, 2018, 10, 452.	1.7	2